Introduction: In peritoneal dialysis (PD), managing peritoneal glucose uptake is a clinical challenge, as the uptake leads to peritoneal ultrafiltration loss. Peritoneal expression of sodium-glucose co-transporter 2 (SGLT2) suggests that SGLT2 inhibitors, a class of antidiabetic agents, may offer a solution. Methods: In 12 PD patients, we examined the influence of dapagliflozin, an SGLT2 inhibitor, on peritoneal equilibration test. Results: The volume of drainage and the total glucose content in drainage were larger in the test with dapagliflozin than in that without dapagliflozin (2.41 ± 0.16 vs. 2.23 ± 0.20 L, p = 0.011 and 16.9 ± 3.8 vs. 14.5 ± 3.7 g, p = 0.005, respectively). Conclusion: SGLT2 inhibitors could reduce peritoneal glucose uptake and improve fluid removal in clinical PD.

1.
Krediet
RT
.
Acquired decline in ultrafiltration in peritoneal dialysis: the role of glucose
.
J Am Soc Nephrol
.
2021
;
32
(
10
):
2408
15
.
2.
Holmes
CJ
,
Shockley
TR
.
Strategies to reduce glucose exposure in peritoneal dialysis patients
.
Perit Dial Int
.
2000
;
20
(
2_Suppl l
):
S37
41
.
3.
Wright
EM
.
SGLT2 inhibitors: physiology and pharmacology
.
Kidney360
.
2021
;
2
(
12
):
2027
37
.
4.
Schricker
S
,
Oberacker
T
,
Fritz
P
,
Ketteler
M
,
Alscher
MD
,
Schanz
M
.
Peritoneal expression of SGLT-2, GLUT1, and GLUT3 in peritoneal dialysis patients
.
Kidney Blood Press Res
.
2022
;
47
(
2
):
125
34
.
5.
Lai
JW
,
Lin
HJ
,
Chou
CY
.
SGLT-2 inhibitors may increase ultrafiltration in incident peritoneal dialysis patients: a case report
.
BMC Nephrol
.
2023
;
24
(
1
):
106
.
6.
Zhou
Y
,
Fan
J
,
Zheng
C
,
Yin
P
,
Wu
H
,
Li
X
, et al
.
SGLT-2 inhibitors reduce glucose absorption from peritoneal dialysis solution by suppressing the activity of SGLT-2
.
Biomed Pharmacother
.
2019
;
109
:
1327
38
.
7.
Martus
G
,
Bergling
K
,
de Arteaga
J
,
Öberg
CM
.
SGLT2 inhibition does not reduce glucose absorption during experimental peritoneal dialysis
.
Perit Dial Int
.
2021
;
41
(
4
):
373
80
.
8.
Vorobiov
M
,
Rogachev
B
,
Riff
R
,
Chaimowitz
C
,
Neulander
EZ
,
Basok
A
, et al
.
Blockade of sodium-glucose co-transporters improves peritoneal ultrafiltration in uraemic rodent models
.
Perit Dial Int
.
2024
;
44
(
1
):
48
55
.
9.
Martus
G
,
Bergling
K
,
Öberg
CM
.
Dual SGLT1/SGLT2 inhibitor phlorizin reduces glucose transport in experimental peritoneal dialysis
.
Perit Dial Int
.
2023
;
43
(
2
):
145
50
.
10.
Dominguez Rieg
JA
,
Rieg
T
.
What does sodium-glucose co-transporter 1 inhibition add: prospects for dual inhibition
.
Diabetes Obes Metab
.
2019
;
21
(
Suppl 2
):
S43
52
.
11.
Plosker
GL
.
Dapagliflozin: a review of its use in type 2 diabetes mellitus
.
Drugs
.
2012
;
72
(
17
):
2289
312
.
12.
Kasichayanula
S
,
Liu
X
,
Lacreta
F
,
Griffen
SC
,
Boulton
DW
.
Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2
.
Clin Pharmacokinet
.
2014
;
53
(
1
):
17
27
.
13.
McMurray
JJV
,
Solomon
SD
,
Inzucchi
SE
,
Køber
L
,
Kosiborod
MN
,
Martinez
FA
, et al
.
Dapagliflozin in patients with heart failure and reduced ejection fraction
.
N Engl J Med
.
2019
;
381
(
21
):
1995
2008
.
14.
Anker
SD
,
Butler
J
,
Filippatos
G
,
Khan
MS
,
Marx
N
,
Lam
CSP
, et al
.
Effect of empagliflozin on cardiovascular and renal outcomes in patients with heart failure by baseline diabetes status: results from the EMPEROR-reduced trial
.
Circulation
.
2021
;
143
(
4
):
337
49
.
15.
Lo
WK
,
Brendolan
A
,
Prowant
BF
,
Moore
HL
,
Khanna
R
,
Twardowski
ZJ
, et al
.
Changes in the peritoneal equilibration test in selected chronic peritoneal dialysis patients
.
J Am Soc Nephrol
.
1994
;
4
(
7
):
1466
74
.
You do not currently have access to this content.